Imagine trying to solve a complex puzzle with multiple pieces that fit together perfectly. That’s what scientists did in this study on the mechanism of donepezil in treating Alzheimer’s disease (AD). Using network pharmacology and molecular docking, they collected compounds and targets associated with donepezil from various databases. They then created an interactive network that revealed the intricate relationship between the drug and its targets. Through enrichment analyses, they unveiled the functions and mechanisms by which donepezil operates. The study identified key targets and signaling pathways involved in chemical synaptic transmission and cell proliferation, differentiation, and survival. These findings highlight the multi-component, multi-target, and multi-pathway nature of donepezil’s therapeutic effects. This research offers promising insights into how donepezil can help in the treatment of AD.
ObjectiveIn order to explore and further understand the efficacy of donepezil (DNP) in the treatment of Alzheimer’s disease (AD), this research was conducted based on network pharmacology and molecular docking.MethodCompounds of DNP and its effective targets were collected using the TCMSP Chinese medicine system pharmacology database. Disease targets were screened and selected utilizing GeneCards, TTD, DrugBank, CTD, and other online databases. Then, Venn diagrams were generated to identify the intersections. A diseases-drug-active ingredient-key target protein interaction (PPI) network was constructed using the STING database. GO and KEGG enrichment analyses were conducted to predict the function and mechanism of DNP, which were visualized by graphs and bubble charts. After the screening, the top five interacting targets in the PPI network and the compound containing the most active target were selected for molecular docking.ResultsThe study received 110 potential targeting genes and 155 signaling pathways. A strong association between DNP and modulation of chemical synaptic transmission and the regulation of trans-synaptic signaling is noted. Signaling pathways related to the proliferation, differentiation, and survival of cells are also found positively relative. The results revealed that the mechanism of its therapeutic effect is multi-component, multi-target, and multi-pathway, laying a foundation for the follow-up in-depth study of the mechanism of DNP in the treatment of AD.ConclusionThis research provides a superior prediction that AD could be treated using DNP which targets the key proteins and essential pathways associated with the recovery of AD.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.